Gene: PKD1L2

114780
PC1L2
polycystin 1 like 2 (gene/pseudogene)
protein-coding
16q23.2
Ensembl:ENSG00000166473 MIM:607894 Vega:OTTHUMG00000166126 UniprotKB:Q7Z442
NG_033236.1
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.006e-2 (AD)  6.050e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs8044334chr16:81215330 (GRCh38.p7)T>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HSD17B30.765
KCNH80.736
PLXNB30.736
USP540.728
SEMA6A0.721
TTYH20.716
CLMN0.709
COL4A50.708
TMTC20.703
PLEKHH10.702

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CRH-0.349
PNOC-0.344
NDNF-0.332
NPBWR1-0.328
DLX5-0.328
CHRNA2-0.327
GPR153-0.327
CALB2-0.314
PRTN3-0.312
IGF1-0.308

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
D000452AldrinAldrin results in decreased expression of PKD1L2 mRNA18579281
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of PKD1L2 mRNA24449571
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PKD1L2 mRNA22300585
C006780bisphenol Abisphenol A results in increased expression of PKD1L2 mRNA27685785
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PKD1L2 mRNA28628672
C006780bisphenol Abisphenol A results in decreased expression of PKD1L2 mRNA26063408
C006780bisphenol Abisphenol A results in decreased methylation of PKD1L2 promoter27312807
C006780bisphenol Abisphenol A results in increased methylation of PKD1L2 promoter27312807
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of PKD1L2 mRNA28628672
C018475butyraldehydebutyraldehyde results in decreased expression of PKD1L2 mRNA26079696
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in increased expression of PKD1L2 mRNA26272509
D002994ClofibrateClofibrate results in decreased expression of PKD1L2 mRNA22300585
C014347decitabinedecitabine affects the expression of PKD1L2 mRNA23300844
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PKD1L2 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of PKD1L2 mRNA28628672
D002945CisplatinCisplatin affects the expression of PKD1L2 mRNA23300844
D002945CisplatinCisplatin results in decreased expression of PKD1L2 mRNA27392435
C000944dicrotophosdicrotophos results in increased expression of PKD1L2 mRNA28302478
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of PKD1L2 mRNA23649840
D005557FormaldehydeFormaldehyde results in increased expression of PKD1L2 mRNA23649840
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PKD1L2 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of PKD1L2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PKD1L2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of PKD1L2 mRNA28628672
C544151jinfukangjinfukang results in increased expression of PKD1L2 mRNA27392435
D008070Lipopolysaccharides[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of PKD1L2 gene21212295
C042720mercuric bromidemercuric bromide results in increased expression of PKD1L2 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of PKD1L2 mRNA23649840
C046012pentanalpentanal results in decreased expression of PKD1L2 mRNA26079696
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKD1L2 mRNA"27188386
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of PKD1L2 mRNA25895662
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of PKD1L2 gene21212295
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate affects the expression of PKD1L2 mRNA"26179874
D014520UrethaneUrethane results in decreased expression of PKD1L2 mRNA28818685
D014635Valproic AcidValproic Acid results in decreased expression of PKD1L2 mRNA24383497
D014635Valproic AcidValproic Acid results in increased methylation of PKD1L2 gene29154799
D014752Vinyl ChlorideVinyl Chloride results in decreased expression of PKD1L2 mRNA18579281

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005262calcium channel activity-IBA21873635  
GO:0005509calcium ion binding-IEA-  
GO:0030246carbohydrate binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0050982detection of mechanical stimulus-IBA21873635  
GO:0070588calcium ion transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0016020membrane-IBA21873635  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal